Yeda Research and Develpment & Co. Ltd

Dan Aderka

David Wallach

Hartmut Engelmann

Menachem Rubinstein

Michel Revel

Daniela Novick

Cord Brakebusch

Oliver Kemper

Yasmin Maor

Harmut Engelmann

Yaron Nophar

An isolated DNA molecule has the sequence of encoding a fragment of encoding Tumor Necrosis Factor (TNF) Binding Protein II. It has a length sufficient to serve as an immunogen for raising antibodies against a polypeptide that is a fragment of TNF Binding Protein II. The DNA may be used to produce replicable expression vehicles and prokaryotic or eukaryotic expression host cells. Such host cells may be used to produce polypeptides encoded by such DNA molecules.

Isolated cDNA encoding tumor necrosis factor binding protein II, its purification, and vectors, hosts and processes using such cDNA

Tumor necrosis factor inhibitory protein and its purification

Tumor Necrosis Factor (TNF) Inhibitory Protein is isolated and substantially purified. It has the ability to inhibit: (a) the binding of TNF to its receptors, and (b) the cytotoxic effect of TNF. TNF Inhibitory Protein and salts, functional derivatives and active fractions thereof can be used to antagonize the deleterious effects of TNF.

Tumor Necrosis Factor Binding Protein I (TBP-I), precursors and analogs thereof, are produced by transfecting eukaryotic cells with an expression vector comprising al DNA molecule encoding the whole human type I TNF receptor or a soluble domain thereof, and culturing the transfected cells, whereby the soluble proteins are secreted into the medium.

Expression of the recombinant tumor necrosis factor binding protein I

Tumor Necrosis Factor (TNF) Inhibitory Protein is isolated and substantially purified and the DNA that encodes the TNF inhibitory protein, vectors, host cells, and a recombinant method for producing the encoded protein are also set forth. It has the ability to inhibit: (a) the binding of TNF to its receptors, and (b) the cytotoxic effect of TNF. TNF Inhibitory Protein and salts, functional derivatives and active fractions thereof can be used to antagonize the deleterious effects of TNF.

DNA that encodes a tumor necrosis factor inhibitory protein and a

Tumor Necrosis Factor Binding Proteins (TBPs) are useful in the treatment of autoimmune diseases and graft-versus-host reactions.

Pharmaceutical compositions comprising an anticytokine

The use of interleukin-6 and/or salts, functional derivatives, muteins or active fractions thereof, in the treatment of chronic lymphocytic leukemia and B-cell lymphomas, as well as such use together with the soluble interleukin-6 receptor, to pharmaceutical compositions and to a method of treating chronic lymphocytic leukemia or B-cell lymphomas.

Use of IL-6 for the treatment of chronic lymphocyte leukemia (CLL) and

Antibodies to TNF Binding Protein I (TBP-I) are provided that can be used in diagnostic assays and as pharmaceutical agents for either inhibiting or mimicking the effects of TNF on cells.

Growing community of inventors

Holon, Israel

Dan Aderka